Date: 2017-01-17
Type of information: Opening of new premises
Compound: new facility in Mollet des Vallès (Spain)
Company: Merck KGaA (Germany)
Therapeutic area:
Type agreement: opening of new premises
Action mechanism:
Disease:
Details: * On January 17, 2017, Merck KGaA announced the opening of a facility in Mollet des Vallès, Spain dedicated to the manufacture of meglumine, an FDA-approved excipient for pharmaceuticals and a component of medical imaging contrast media.
The facility, validated by the FDA, is the only location in Europe that manufactures meglumine, an amino sugar derived from glucose. The facility in Spain is solely dedicated to the production of meglumine, thereby ensuring continuity of supply to customers as well as meeting increasing demand for the excipient. As an excipient, meglumine interacts directly with active pharmaceutical ingredients to increase solubility. Therefore, the manufacture of meglumine must meet the same stringent regulatory and quality requirements as APIs.
Financial terms:
Latest news:
